257 related articles for article (PubMed ID: 11231916)
1. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
Chen Z; Ishibashi S; Perrey S; Osuga Ji ; Gotoda T; Kitamine T; Tamura Y; Okazaki H; Yahagi N; Iizuka Y; Shionoiri F; Ohashi K; Harada K; Shimano H; Nagai R; Yamada N
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):372-7. PubMed ID: 11231916
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Collins AR; Meehan WP; Kintscher U; Jackson S; Wakino S; Noh G; Palinski W; Hsueh WA; Law RE
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):365-71. PubMed ID: 11231915
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
4. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.
Marleau S; Harb D; Bujold K; Avallone R; Iken K; Wang Y; Demers A; Sirois MG; Febbraio M; Silverstein RL; Tremblay A; Ong H
FASEB J; 2005 Nov; 19(13):1869-71. PubMed ID: 16123174
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone action is independent of adipose tissue.
Burant CF; Sreenan S; Hirano K; Tai TA; Lohmiller J; Lukens J; Davidson NO; Ross S; Graves RA
J Clin Invest; 1997 Dec; 100(11):2900-8. PubMed ID: 9389757
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Park KS; Ciaraldi TP; Lindgren K; Abrams-Carter L; Mudaliar S; Nikoulina SE; Tufari SR; Veerkamp JH; Vidal-Puig A; Henry RR
J Clin Endocrinol Metab; 1998 Aug; 83(8):2830-5. PubMed ID: 9709955
[TBL] [Abstract][Full Text] [Related]
8. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.
Davies GF; McFie PJ; Khandelwal RL; Roesler WJ
J Pharmacol Exp Ther; 2002 Jan; 300(1):72-7. PubMed ID: 11752099
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
[TBL] [Abstract][Full Text] [Related]
10. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
[TBL] [Abstract][Full Text] [Related]
11. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase.
Kobayashi J; Nagashima I; Hikita M; Bujo H; Takahashi K; Otabe M; Morisaki N; Saito Y
Br J Clin Pharmacol; 1999 Apr; 47(4):433-9. PubMed ID: 10233209
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y; Itoh H; Doi K; Tanaka T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Sawada N; Saito T; Hosoda K; Kook H; Ueda M; Nakao K
Atherosclerosis; 2001 Sep; 158(1):113-9. PubMed ID: 11500181
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice.
Zhang W; Yancey PG; Su YR; Babaev VR; Zhang Y; Fazio S; Linton MF
Circulation; 2003 Nov; 108(18):2258-63. PubMed ID: 14581413
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.
Wang M; Wise SC; Leff T; Su TZ
Diabetes; 1999 Feb; 48(2):254-60. PubMed ID: 10334298
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
Raji A; Plutzky J
Curr Cardiol Rep; 2002 Nov; 4(6):514-21. PubMed ID: 12379175
[TBL] [Abstract][Full Text] [Related]
17. Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Suzuki A; Yasuno T; Kojo H; Hirosumi J; Mutoh S; Notsu Y
Jpn J Pharmacol; 2000 Oct; 84(2):113-23. PubMed ID: 11128033
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells.
de Dios ST; Hannan KM; Dilley RJ; Hill MA; Little PJ
J Diabetes Complications; 2001; 15(3):120-7. PubMed ID: 11358680
[TBL] [Abstract][Full Text] [Related]
19. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Sugawara A; Takeuchi K; Uruno A; Ikeda Y; Arima S; Sato K; Kudo M; Taniyama Y; Ito S
Hypertens Res; 2001 May; 24(3):229-33. PubMed ID: 11409645
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
